Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 921-927

  Foweraker, Juliet E ^a   Laughton, C R ^a   Brown, D F J ^b   Bilton, D ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

CF; P. aeruginosa; Susceptibility testing

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; TOBRAMYCIN;

ACUTE DISEASE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM COLONY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DIFFUSION; DISEASE EXACERBATION; GENOTYPE; GRAM NEGATIVE INFECTION; HUMAN; LUNG INFECTION; PHENOTYPIC VARIATION; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY; SPUTUM ANALYSIS; SPUTUM CULTURE; VALIDATION PROCESS;

ACUTE DISEASE; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY OF RESULTS; SPUTUM;

EID: 21244451543     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki146     Document Type: Article

References (22)

1. Breitenstein S, Walter S, Bosshammer J et al. Direct sputum analysis of Pseudomonas aeruginosa macrorestriction fragment geno-types in patients with cystic fibrosis. Med Microbiol Immunol 1997; 186: 95-9.
2. Wolter J, Kotsiou G, McCormack J. Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. J Med Microbiol 1995; 42: 220-4.
3. Regelmann W, Elliott G, Warwick W et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Resp Dis 1990; 141: 914-21.
4. Smith A, Doershuk C, Goldmann D et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-21.
5. Smith A, Fiel S, Mayer-Hamblett N et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration. Lack of association in cystic fibrosis. Chest 2003; 123: 1495-502.
6. Andrews J. BSAC standardized disc susceptibility testing method (version 3). J Antimicrob Chemother 2004; 53: 713-28.
7. Thomassen M, Demko C, Boxerbaum B et al. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979; 140: 873-80.
8. Fyfe J, Govan J. Chromosomal loci associated with antibiotic hypersensitivity in pulmonary isolates of Pseudomonas aeruginosa. J Gen Microbiol 1984; 130: 825-34.
9. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis: Report of the UK Cystic Fibrosis Trust's Antibiotic Group. Bromley, Kent: CF Trust, 2000.
10. Van-Horn K. Mixed-morphotype broth microdilution susceptibility testing of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Microbiol 1993; 31: 458-9.
11. Morlin G, Hedges D, Smith A et al. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. J Clin Microbiol 1994; 32: 1027-30.
12. Jain M, Ramirez D, Seshardri R et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with Cystic Fibrosis. J Clin Microbiol 2004; 42: 5229-37.
13. Drenkard E, Ausubel F. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
14. Haussler S, Ziegler I, Lottel A et al. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J Med Microbiol 2003; 52: 295-301.
15. Oliver A, Canton R, Campo P et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
16. Govan J, Nelson J. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992; 48: 912-30.
17. Gilligan P. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35-51.
18. Serisier DJ, Jones G, Tuck A et al. Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis. Pediatr Pulmonol 2003; 35: 463-6.
19. Ceri H, Olson ME, Stremick C et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
20. Lang BJ, Aaron SD, Ferris W et al. Multiple combination bacteriocidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. American J Resp Crit Care Med 2000; 162: 2241-5.
21. Muscovitz SM, Foster JM, Emerson J et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42: 1915-22.
22. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677-83.